
Importance of Synchronized approach on the implementation of the IMDRF recommendations





Moscow, March 2019





About IMEDA

IMEDA (International Medical Device Manufacturers Association) – A non-profit organization uniting international manufacturers of medical equipment, products, and consumables on the Russian market founded in 2005

IMEDA – common voice of international manufacturers of Medical Devices in **RUSSIA**

Almost 25% of our members – localized in Russia



IMEDA's Mission

Improving the efficiency of the Health Care System by introducing new technologies and providing the Russian population with modern, high-quality and affordable medical devices

Today the Association unites more than 50 leading international companies operating in the field of high-tech medicine in RUSSIA



The International Medical Device Regulators Forum (IMDRF) -

it was established in February 2011 in order to harmonize regulatory requirements for the treatment of medical devices at the international level.

IMDRF Management Committee – the Supreme body of the Forum consisting of official representatives of 10 regulatory bodies of the participating countries.

The current members are: Australia Brazil Canada China Europe Japan **Russia (November, 2013)** Singapore South Korea, and the United States of America.





Common achievement

<u>Regulatory Authority + Industry = Open Dialogue</u>

2-3 times per year we have joint meetings

All issues related to circulation of MDs thoroughly discussed

<u>Next steps:</u> some elements of Tech Files/Instruction of Use content for further progress in terms of IMDRF requirements synchronization need to be discussed



IMDRF topics cover all aspects related to the

regulation of MDs:

- 1. Documents submission (Tech Files/Instruction of Use)
- 2. Registration
- 3. Labeling
- 4. Standards
- 5. Clinical Evaluation
- 6. Quality Management System
- 7. Medical Software
- 8. etc.



The major TASK for Regulatory Authority

To find the BALANCE between the Scope of all SAFETY requirements for market access vs Market Development & Affordability of the State of the Art products to patients

<u>Getting this task resolved will for sure</u> result into the positive development of the market



Risks of an unsynchronized approach

Different requirements globally

Excessive pressure on business

Increase the cost of products

Delayed product launch/market access



EDA Synchronized implementation of IMDRF recommendations

Less costs for business/HC System/patient

Accelerated product launch to the market

Everyone speaks the same language

as a foundation to support and develop a future global single submission format

Outcome: win-win-win situation



Conclusion

 ✓ Synchronized implementation of the best IMDRF regulatory practices globally will lead to transparent & predictable regulatory environment

✓ Regulatory harmonization across jurisdictions is key to ensure stable supply of save & efficient high-tech products to the market



imeda@imeda.ru www.imeda.ru

